AstraZeneca has completed a $140 million equity investment in Cellectis, a biotech firm at the forefront of gene-editing therapies. This transaction, which follows approval from the French Ministry of Economy, sees AstraZeneca acquiring 10 million Class A and 18 million Class B convertible preferred shares at $5 each. The Class A shares carry single voting…